Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Amortizatization of Intangibles (2016 - 2025)

Guided Therapeutics' Amortizatization of Intangibles history spans 10 years, with the latest figure at $25000.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles rose 13.64% year-over-year to $25000.0; the TTM value through Sep 2025 reached $94000.0, up 11.9%, while the annual FY2024 figure was $86000.0, 13.16% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $25000.0 at Guided Therapeutics, up from $24000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $58000.0 in Q3 2021 and bottomed at $8000.0 in Q2 2021.
  • The 5-year median for Amortizatization of Intangibles is $19500.0 (2023), against an average of $21333.3.
  • The largest YoY upside for Amortizatization of Intangibles was 209.43% in 2021 against a maximum downside of 76.47% in 2021.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $16000.0 in 2021, then grew by 12.5% to $18000.0 in 2022, then increased by 11.11% to $20000.0 in 2023, then increased by 10.0% to $22000.0 in 2024, then grew by 13.64% to $25000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Amortizatization of Intangibles are $25000.0 (Q3 2025), $24000.0 (Q2 2025), and $23000.0 (Q1 2025).